The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.
 
Glenn J. Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Bristol-Myers Squibb; Kura Oncology
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Exicure; General Catalyst; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Prelude Therapeutics; Rain Therapeutics; Remix Therapeutics; Sanofi; SIRPant Immunotherapeutics
Research Funding - Actuate Therapeutics (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); Secura Bio (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch; Ahmuty, Demers, & McManus; Wilson Elser Moskowitz Edelman & Dicker, LLP
 
John M. Kaczmar
Stock and Other Ownership Interests - HCA Healthcare (I)
Honoraria - The Scienomics Group; Triangle Insights Group
Consulting or Advisory Role - Bicara Therapeutics; Coherus Biosciences; Rakuten Medical
 
Dan Paul Zandberg
Consulting or Advisory Role - Blueprint Medicines; Macrogenics; Merck; Prelude Therapeutics
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
Deborah J.L. Wong
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Genentech/Roche; Regeneron; Sanofi/Aventis
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); FSTAR (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Kura Oncology (Inst); Lilly; Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst); TopAlliance BioSciences Inc (Inst)
 
Emrullah Yilmaz
Consulting or Advisory Role - Astellas Pharma
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron (Inst)
 
Alberto Hernando-Calvo
Travel, Accommodations, Expenses - Kyowa Kirin International; Merck Serono
 
Assuntina G. Sacco
Employment - Moores Cancer Center
Consulting or Advisory Role - Bicara Therapeutics
Research Funding - Bicara Therapeutics (Inst); Merck (Inst); Nektar (Inst)
 
Christine H. Chung
Consulting or Advisory Role - Brooklyn ImmunoTherapeutics; Exelixis; Fulgent Pharma; Genmab; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Brooklyn ImmunoTherapeutics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Regeneron (Inst)
 
David Bohr
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics; Bristol Myers Squibb Foundation; Gilead Sciences; Johnson & Johnson/Janssen
 
Ralf Reiners
Employment - Bicara Therapeutics; Novartis (I)
Stock and Other Ownership Interests - Bicara Therapeutics; Novartis (I)
 
Rachel Salazar
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics
Travel, Accommodations, Expenses - Bicara Therapeutics
 
Elham Gharakhani
Employment - Bicara Therapeutics; Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - Bicara Therapeutics; Biogen
 
Sanela Bilic
Consulting or Advisory Role - Bicara Therapeutics (Inst)
 
Jameel Muzaffar
No Relationships to Disclose